[en] Objectives: To collect recent data on the susceptibility of anaerobes to antimicrobial agents with known activity against anaerobes, and to compare them with results from previous Belgian multicentre studies.
Methods: Four hundred and three strict anaerobic clinical isolates were prospectively collected from February 2011 to April 2012 in eight Belgian university hospitals. MICs were determined by one central laboratory for 11 antimicro- bial agents using Etest methodology.
Results: According to EUCAST breakpoints, .90% of isolates were susceptible to amoxicillin/clavulanate (94%), piperacillin/tazobactam (91%), meropenem (96%), metronidazole (92%) and chloramphenicol (98%), but only 70% and 40% to clindamycin and penicillin, respectively. At CLSI recommended breakpoints, only 71% were sus- ceptible to moxifloxacin and 79% to cefoxitin. MIC50/MIC90 values for linezolid and for tigecycline were 1/4 and 0.5/ 4 mg/L, respectively. When compared with survey data from 2004, no major differences in susceptibility profiles were noticed. However, the susceptibility of Prevotella spp. and other Gram-negative bacilli to clindamycin decreased from 91% in 1993 – 94 and 82% in 2004 to 69% in this survey. Furthermore, the susceptibility of clostridia to moxifloxacin decreased from 88% in 2004 to 66% in 2011 – 12 and that of fusobacteria from 90% to 71%.
Conclusions: Compared with previous surveys, little evolution was seen in susceptibility, except a decline in activity of clindamycin against Prevotella spp. and other Gram-negative bacteria, and of moxifloxacin against clostridia. Since resistance was detected to all antibiotics, susceptibility testing of anaerobic isolates is indicated in severe infections to confirm appropriateness of antimicrobial therapy.
Disciplines :
Laboratory medicine & medical technology Immunology & infectious disease
Author, co-author :
Wybo, Ingrid; Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Van den Bossche; Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Soetens, Oriane; Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Vekens, Evilien; Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Vandoorslaer, Kristof; Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Claeys, Geert; Universitair Ziekenhuis Gent - UZ > Department of Microbiologyl
Glupczynski, Youri; Université Catholique de Louvain - UCL > Department of Microbiology - Mont Godinne Dinant
Ieven, margareta; Universitair Ziekenhuis Antwerpen - UZA > Medical microbiology
MELIN, Pierrette ; Centre Hospitalier Universitaire de Liège - CHU > Microbiologie médicale
Nonhoff, Claire; Cliniques Universitaires de Bruxelles - Hôpital Erasme > Department of microbiology
Rodriguez-Villalobos, Hector; Cliniques Universitaires Saint-Luc (Bruxelles) > Department of Microbiology
Verhaegen, Jan; Universitair Ziekenhuis - KUL > Department of Clinical Microbiology
Pierard, Denis; Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Nagy E, Urbán E, Nord CE et al. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011; 17: 371-9.
Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2007.
Piérard D, De Meyer A, Rosseel P et al. In vitro activity of amoxycillin plus clavulanic acid and ticarcillin plus clavulanic acid compared with that of other antibiotics against anaerobic bacteria. Acta Clin Belg 1989; 44: 228-36.
Piérard D, De Meyer A, Rosseel P et al. In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey. Acta Clin Belg 1996; 51: 70-9.
WyboI, Piérard D, VerschraegenI et al. ThirdBelgian multicentre surveyof antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007; 59: 132-9.
Wybo I, Soetens O, De Bel A et al. Species identification of clinical Prevotella isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2012; 50: 1415-8.
Pierard D, De MA, Rosseel P et al. Use of the E-test for determining antimicrobial susceptibility of anaerobic bacteria. Pathol Biol (Paris) 1996; 44: 358-62.
EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. http://www.eucast.org/clinical_breakpoints/(13 July 2013, date last accessed).
US FDA. FDA Approved Drug Products Label for TYGACIL, NDA no. 021821 (approved on 23/05/2013). http://www.accessdata.fda.gov/drugsatfda_ docs/label/2013/021821s037lbl.pdf (13 July 2013, date last accessed).
Só ki J, Fodor E, Hecht DW et al. Molecular characterization of imipenem-resistant, cfiA-positive Bacteroides fragilis isolates from the USA, Hungary and Kuwait. J Med Microbiol 2004; 53: 413-9.
Wybo I, De Bel A, Soetens O et al. Differentiation of cfiA-negative and cfiA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2011; 49: 1961-4.
Trinh S, Reysset G. Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp. J Clin Microbiol 1996; 34: 2078-84.
Theron MM, Janse Van Rensburg MN, Chalkley LJ et al. Nitroimidazole resistance genes (nimB) in aerobic Gram-positive cocci (previously Peptostreptococcus spp.). J Antimicrob Chemother 54: 240-2.
Wybo I, Soetens O, Vandoorslaer K et al. Prevalence of nim-genes in Bacteroides fragilis group in Belgium. Clin Microbiol Infect 2008; 14 Suppl 7: S600 (P2039).
Gal M, Brazier JS. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother 2004; 54: 109-16.
Lofmark S, Fang H, HedbergM et al. Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob Agents Chemother 2005; 49: 1253-6.
Nagy E, Becker S, Só ki J et al. Differentiation of division I (cfiA-negative) and division II (cfiA-positive) Bacteroides fragilis strains by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Med Microbiol 2011; 60: 1584-90.
Glupczynski Y, Berhin C, Nizet H. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-test methodology. Eur J Clin Microbiol Infect Dis 2009; 28: 261-7.
De Waele JJ, Tellado JM, Adler J et al. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. Int J Antimicrob Agents 2013; 41: 57-64.
Behra-Miellet J, Calvet L, Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents 2003; 22: 28-34.
Snydman DR, Jacobus NV, McDermott LA. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis onthe Bacteroides fragilis group. J AntimicrobChemother 2005;55:1024-8.
Salin F, Vianello F, Manara R et al. Linezolid in the treatment of brain abscess due to Peptostreptococcus. Scand J Infect Dis 2006; 38: 203-5.
Wareham DW, Wilks M, Ahmed D et al. Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy. Clin Infect Dis 2005; 40: e67-e68.
